There is abundant evidence for a good response rate to combination chemotherapy in advanced breast cancer, and to endocrine therapy as well if the tumor is receptor-positive. The unresolved issue is whether patient outcomes, such as survival, are improved by combining these two separate approaches. Do the higher complete and partial response rates to combined chemo-endocrine therapy result in longer survival than when these therapies are used in sequence? Can appropriate endocrine manipulation sensitize tumor cells to subsequent treatment? Could there be some disadvantage to combining endocrine and chemotherapy? These questions are discussed here by a selected panel.
ASJC Scopus subject areas
- Cancer Research